Interview with Jan Slob, President, Akrikhin
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Address: 52, bld 5, Kosmodamianskaya Naberezhnaya,Moscow, Russia, 115054,Russia
Tel: + 7 (495) 721 36 97
AKRIKHIN founded in 1936, is one of the leading Russian pharmaceutical producer of high-quality medicines on the Russian pharmaceutical market. By 2010 results AKRIKHIN is the 5th largest local producer by revenue and production volume on the Russian pharmaceutical market.
AKRIKHIN product portfolio counts more than 150 products focused within strategically selected Anatomo Therapeutic Classes including cardiovascular, neurology, dermatology, gynecology, pediatrics. AKRIKHIN produces a wide range of socially important medications thus making a tangible input into the development of the Russian healthcare system. AKRIKHIN is a major Russian producer of Essential Drugs which account up to 70% share of the Company product portfolio. Special emphasis is made on strategic directions of high social value – production of drugs for diabetes and tuberculosis treatment.
With the Company Field Force operating in 76 cities all across Russia and highly professional marketing team AKRIKHIN has succeeded in forming a wide and well-diversified product portfolio well recognized by doctors.
AKRIKHIN production facilities is a consolidated GMP-oriented complex located 30 km from Moscow with the workshops for production of a vast spectre of drug forms: tablets, capsules, ointments, gels, creams, syrups, etc. AKRIKHIN production existing capacities amount to more than 50 mln packs per year.
Starting from 2007 AKRIKHIN entered a strategic alliance with Polpharma – the largest Polish manufacturer of generic drugs and pharmaceutical substances. AKRIKHIN and Polpharma strategic partnership embracesincorporates common product portfolio, production technologies transfer, R&D cooperation, access to best European practices and standards, joint educational programmes for personnel.
In the “Rating of influence of Russian pharmaceutical market participants” based on pharmaceutical market experts’ opinions “AKRIKHIN” is included into the TOP 3 most authoritative and influential Russian pharmaceutical producers upon the results of 2010.
AKRIKHIN priding on its 75-years’ history and traditions builds on its successful performance on the Russian pharmaceutical market, dynamically adapting itself to modern business practices and technologies.
In its portfolio of more than 150 products of various dosage forms: tablets, capsules, creams, suppositories, creams, syrups. Akrihin focuses on therapeutic areas with high social importance, ie most sought-after Russian health care system: cardiology, diabetes, neurology, dermatology, tuberculosis, gynecology and pediatrics
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here